The success of tocilizumab (an anti-IL-6R antibody) and tofacitinib as an inhibitor of JAK/STAT led to the successful use of JAK/STAT targeted therapy in clinics for RA [7,8]. The gene discussed is IL6R; the disease is rheumatoid arthritis.